CUE - CIK 0001645460
Cue Biopharma, Inc. (CUE) reported net income of -$26.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$26.60M | +34.6% |
| FY 2024 | -$40.67M | +19.8% |
| FY 2023 | -$50.73M | +4.3% |
| FY 2022 | -$53.01M | -20.0% |
| FY 2021 | -$44.16M | +1.4% |
| FY 2020 | -$44.78M | -22.0% |
| FY 2019 | -$36.70M | +5.9% |
| FY 2018 | -$38.98M | -67.8% |
| FY 2017 |
Cue Biopharma, Inc. (CUE) reported net income of -$26.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Cue Biopharma, Inc.'s net income declined from -$23.23M to -$26.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$23.23M |
| - |